Puma Biotechnology asserts patent infringement claims against AstraZeneca's Tagrisso® (osimertinib) products for treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer
Clients Puma Biotechnology, Inc.
Jones Day is representing Puma Biotechnology, Inc. in a patent infringement action against defendants for infringement of United States Patent Nos. 10,603,314 and 10,596,162. The complaint alleges that defendants' commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso® (osimertinib) products for the treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer infringes the asserted patents.
Puma Biotechnology, Inc., et al. v. AstraZeneca Pharmaceuticals LP, et al., No. 1-21-cv-01338 (D. Del.)